Emergent Biosolutions Total Assets 2007-2021 | EBS

Emergent Biosolutions total assets from 2007 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Emergent Biosolutions Annual Total Assets
(Millions of US $)
2020 $2,883
2019 $2,327
2018 $2,229
2017 $1,070
2016 $970
2015 $1,037
2014 $939
2013 $627
2012 $564
2011 $547
2010 $500
2009 $345
2008 $291
2007 $274
2006 $238
2005 $100
Emergent Biosolutions Quarterly Total Assets
(Millions of US $)
2021-09-30 $2,868
2021-06-30 $2,915
2021-03-31 $2,900
2020-12-31 $2,883
2020-09-30 $2,616
2020-06-30 $2,466
2020-03-31 $2,279
2019-12-31 $2,327
2019-09-30 $2,334
2019-06-30 $2,321
2019-03-31 $2,154
2018-12-31 $2,229
2018-09-30 $1,174
2018-06-30 $1,139
2018-03-31 $1,068
2017-12-31 $1,070
2017-09-30 $1,024
2017-06-30 $970
2017-03-31 $952
2016-12-31 $970
2016-09-30 $932
2016-06-30 $1,056
2016-03-31 $1,036
2015-12-31 $1,037
2015-09-30 $977
2015-06-30 $943
2015-03-31 $918
2014-12-31 $939
2014-09-30 $869
2014-06-30 $837
2014-03-31 $823
2013-12-31 $627
2013-09-30 $595
2013-06-30 $556
2013-03-31 $538
2012-12-31 $564
2012-09-30 $540
2012-06-30 $527
2012-03-31 $515
2011-12-31 $547
2011-09-30 $513
2011-06-30 $494
2011-03-31 $471
2010-12-31 $500
2010-09-30 $366
2010-06-30 $346
2010-03-31 $343
2009-12-31 $345
2009-09-30 $317
2009-06-30 $326
2009-03-31 $304
2008-12-31 $291
2008-09-30 $287
2008-06-30 $278
2008-03-31 $274
2007-12-31 $274
2007-09-30 $227
2007-06-30 $207
2007-03-31 $204
2006-12-31 $238
2006-09-30 $0
2006-06-30 $0
2006-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.809B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69